Board of Directors


President, Chief Executive Officer and Member of the Board

Dr. Coles joined Onyx in March 2008 as President, Chief Executive Officer, and a member of its board of directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc, including Vice President of the Hypertension and Heart Failure Business Group.

Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master’s degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees, as well as a member of the board of trustees for Johns Hopkins Medicine. Dr. Coles is also a member of the board of directors for Laboratory Corporation of America (LabCorp), as well as Campus Crest Communities, Inc., both NYSE traded companies. He is also a member of the board of the Biotechnology Industry Organization (BIO).


Lead Director

Chairman and CEO, ARYx Therapeutics, Inc., Chairman, AP Pharma and Director, Adolor Corporation

Paul Goddard, Ph.D. has served as a Director since February 1997. From March 2000 to March 2002, Dr. Goddard served as a consultant and advisor to Elan plc. From August 1998 to March 2000, Dr. Goddard served as President and Chief Executive Officer of Elan Pharmaceuticals, Inc., a biotechnology company and a division of Elan plc. From March 1991 to August 1998, Dr. Goddard served as Chief Executive Officer and Chairman of the Board of Neurex Corporation, a biotechnology company, until Neurex Corporation was acquired by Elan Corporation plc. Dr. Goddard is Chairman of the Board of Directors of AP Pharma and Chairman and CEO of ARYx Therapeutics, Inc. Dr. Goddard serves on the Board of Directors of Molecular Devices Corporation and Adolor Corporation. He completed his Ph.D. in the area of Etiology and Pathophysiology of colon cancer at St. Mary’s Hospital, University of London.


Former Chairman, Neoplastic and Autoimmune Diseases Research Institute

Antonio J. Grillo-López, M.D. has served as a Director since September 2002. From November 1992 to January 2001, Dr. Grillo-López served as Chief Medical Officer of IDEC Pharmaceuticals Corporation and from January 2001 to November 2003 held the position of Chief Medical Officer Emeritus of IDEC Pharmaceuticals Corporation. Dr. Grillo-López serves on the Boards of Directors of Favrille, Inc. and Salmedix, Inc., and on the scientific advisory boards of Favrille, Inc., Conforma Therapeutics Corporation, SuperGen, Inc., Salmedix, Inc., Seattle Genetics, Inc., Attenuon LLC and Nereus Pharmaceuticals. Dr. Grillo-López holds a B.S. and an M.D. from the University of Puerto Rico.


Chief Executive Officer, Phadia Group

Magnus Lundberg has served as a Director since June 2000. Since April 2004, Mr. Lundberg has served as President and Chief Executive Officer of Phadia Group, previously Pharmacia Diagnostics AB, a privately held diagnostic company, and formerly a division of Pfizer Inc., a pharmaceutical company. From March 1999 to April 2004, Mr. Lundberg served as President and Chief Executive Officer of Pharmacia Diagnostics AB, while it was a division of Pfizer. From September 1996 to March 1999, Mr. Lundberg served as President of both Chiron Therapeutics and Chiron Vaccines, each a division of Chiron Corporation, a biotechnology company. From 1981 to September 1996, Mr. Lundberg held various management positions at Pharmacia AB, a pharmaceutical company. Mr. Lundberg holds an M.Sc. in Biology and Biochemistry from Abo Akademi in Turku, Finland.


General Partner, LMNVC LLC

Corinne Nevinny has served as a Director since October 2005. She was most recently corporate vice president and the general manager of the Cardiac Surgery Systems and Vascular business units at Edwards Lifesciences Corporation. Prior to assuming that position, she was responsible for the company’s global operations. Prior to joining Edwards in March 2003, Ms. Nevinny was Vice President and Chief Financial Officer of Tularik, Inc, a biotechnology company, for five years. From 1996 until 1998, Ms. Nevinny was Executive Director for the health care group at Warburg Dillon Read LLC, an investment bank. From 1994 to 1996, she was Senior Vice President for the health care group at PaineWebber, Inc., an investment bank. Ms. Nevinny serves on the Board of Directors of Neurocrine Biosciences, Inc., a biopharmaceutical company. Ms. Nevinny received her undergraduate degree from Stanford University and her MBA from Harvard Business School.


Executive Director, Sofinnova Ventures and Senior Advisor, Barclays Capital

Bill Ringo joined as a Director in February 2011. Mr. Ringo has 38 years of experience in the pharmaceutical, biotechnology and med-tech industries. Prior to his most recent assignments, he served as senior vice president of strategy and business development for Pfizer, retiring in 2010. He also spent 28 years at Eli Lilly & Company, serving as product group president for oncology and critical care, president of the infectious diseases business unit, vice president of sales and marketing for U.S. Pharmaceuticals, and as a member of the corporate operating committee. Mr. Ringo was the former president and chief executive officer of Abgenix, a biotechnology firm focused on developing human antibodies to treat cancer that was acquired by Amgen in April 2006. He is the current chairman of Sangamo BioSciences and serves as a director on the Alvine Pharmaceuticals, Inc. and BioCrossroads boards. Mr. Ringo holds a bachelor’s degree and masters in business administration from the University of Dayton.


Executive Vice President, Research and Development, Ambit Biosciences

Wendell Wierenga, Ph.D. has served as a Director of the Company since December 1996. Since January 2007, Dr. Wierenga has served as Executive Vice President, Research and Development of Ambit Biosciences. Previously, he was Executive Vice President, Research and Development of Neurocrine Biosciences, Inc. From September 2000 to August 2003, Dr. Wierenga served as the Chief Executive Officer of Syrrx, Inc., a biotechnology company. From February 1999 to August 2000, Dr. Wierenga served as Senior Vice President, Worldwide Pharmaceutical Sciences, Technologies and Development for the Parke-Davis Pharmaceutical Research division of Warner-Lambert Company, a subsidiary of Pfizer Inc., and from 1990 to February 1999 as Senior Vice President of Research of Parke-Davis. Dr. Wierenga served as Vice President of Medtech Ventures of Warner-Lambert, a pharmaceutical company, from 1992 to 2000. Dr. Wierenga also serves on the Board of Directors of XenoPort, Inc. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in chemistry from Stanford University.


Former Chairman and CEO, Peplin, Inc., and Connetics Corporation

Thomas G. Wiggans has served as a Director of the Company since March 2005. Mr. Wiggans was most recently Chairman and Chief Executive Officer of Peplin, Inc., and prior to that he was the Chairman and Chief Executive Officer of Connetics Corporation. Prior to Connetics, Mr. Wiggans was President and Chief Operating Officer of Cytotherapeutics, Inc., a biotechnology company. Earlier in his career, Mr. Wiggans served in various positions at the Ares-Serono Group, including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Before joining Ares-Serono, he held sales and marketing positions with Eli Lilly and Company. In addition, he serves as Chairman of the Biotechnology Institute, a non-profit educational organization, and Chairman of the Board of Excaliard Pharmaceuticals. He is also a member of the Board of Directors of Sangamo BioSciences, and Somaxon Pharmaceuticals. Mr. Wiggans received his B.S. in Pharmacy from the University of Kansas, and his M.B.A. from Southern Methodist University.

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
  • Last
    43.71 +0.22
  • Open
  • High
  • Low
  • Volume